A study of the safety and survival of the adoptive transfer of genetically marked syngeneic lymphocytes in HIV-infected identical twins.
This phase I/II pilot project will evaluate the survival, tolerance, safety, and efficacy of infusions of activated, gene marked, syngeneic T lymphocytes obtained from HIV seronegative identical twins on the functional immune status of HIV infected twin recipients. T cells from each seronegative twin will be obtained by periodic apheresis, separated into CD4 and CD8 enriched populations by monoclonal antibody affinity binding techniques, induced to polyclonal proliferation with anti-CD3 and rIL-2 stimulation, transduced with distinctive neoR retroviral vectors, and expanded 10-1,000 fold in numbers during approximately 2 weeks of culture. These marked T cell fractions will then be infused into the seropositive twins and the survival of the uniquely marked T cell populations will be monitored by vector-specific PCR, while the recipients' functional immune status is monitored by standard in vitro and in vivo testing protocols. A total of 3 cycles of treatment will be given at intervals of 6 weeks between infusions.
Walker
R
R
Blaese
R M
RM
Carter
C S
CS
Chang
L
L
Klein
H
H
Lane
H C
HC
Leitman
S F
SF
Mullen
C A
CA
Larson
M
M
D000293:Adolescent; D000328:Adult; D000619:Aminohydrolases / Q000235:genetics; D000818:Animals; D001483:Base Sequence; D002470:Cell Survival; D002985:Clinical Protocols; D017931:DNA Primers; D004200:Diseases in Twins / Q000628:therapy*; D005240:Feasibility Studies; D015316:Genetic Therapy; D015658:HIV Infections / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D018023:HIV Seronegativity; D006801:Humans; D016219:Immunotherapy, Adoptive; D008213:Lymphocyte Activation; D017710:Lymphocyte Transfusion; D008253:Macaca mulatta; D008969:Molecular Sequence Data; D012449:Safety; D014430:Twins, Monozygotic
D017931:DNA Primers; D000619:Aminohydrolases; C018774:adenine deaminase